The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

The FDA is assessing the need for “further regulatory action” on Sarepta's Duchenne muscular dystrophy gene therapy in the ...